Artificial Intelligence in Drug Discovery Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

The global artificial intelligence in drug discovery market was valued at USD 2.55 Billion in 2025. It is poised to grow at a CAGR of 28.70% during the forecast period of 2026-2035, and reach USD 31.79 Billion by 2035. The market growth is driven by the increasing research and development costs and timelines, coupled with AI’s ability to accelerate target identification, optimize compounds, and predict outcomes. This adoption significantly improves efficiency, reduces failures, and enables faster drug development.

Key Market Trends and Insights

• Based on the process, the lead optimization segment held nearly 52% market share in the historical period.
• By application, the oncology segment held the leading position, capturing a revenue share of nearly 24% in the historical period.
• Based on the end user, the pharmaceutical and biotechnology companies segment emerged as the dominant end user, representing a revenue share of above 59% during the historical period.

Market Size and Forecast

• Market Size (2025): USD 2.55 Billion
• Projected Market Size (2035): USD 31.79 Billion
• CAGR (2026-2035): 28.70%

Artificial Intelligence in Drug Discovery Market Overview

Artificial Intelligence (AI) plays a transformative role in drug discovery by accelerating target identification, optimizing lead compounds, and predicting clinical outcomes with greater accuracy. It reduces time and costs associated with traditional R&D processes while minimizing failure rates. The market is poised to grow at a CAGR of 28.70% during the forecast period of 2026-2035, due to strong pharmaceutical and biotechnology presence, well-established infrastructure, and significant R&D investments. Strategic collaborations, increasing funding, and AI-driven platforms are enhancing efficiency, supporting precision medicine, and accelerating the overall drug discovery pipeline, positioning the market for substantial expansion during the forecast period.

Artificial Intelligence in Drug Discovery Market Growth Drivers

Rising Strategic Investment Catalyzing AI Driven Drug Discovery is Likely to Enhance the Market Landscape

The growing demand to reduce R&D timelines and rising investor confidence in AI for pharmaceutical innovation are driving significant capital inflows into drug discovery platforms. For instance, in March 2025, Alphabet’s Isomorphic Labs raised USD 600 million in its first funding round for the AI drug business, the Alphabet‑backed AI drug discovery firm secured its first external financing of USD 600 million led by Thrive Capital, with support from Alphabet and Google Ventures. The funding will accelerate development of its next‑generation AI drug design engine, including protein structure prediction, ADMET prediction, and de novo drug design capabilities, and advance therapeutic programs toward clinical trials. This investment underscores heightened confidence in AI’s ability to transform drug discovery and is expected to drive broader AI adoption and innovation throughout the forecast period.

Artificial Intelligence in Drug Discovery Market Trends

Key trends shaping the market include growing collaborations.

Increasing Strategic Collaborations Involving the AI Adoption in Drug Discovery to Boost Market Growth

Rising R&D costs and the increasing need to shorten drug development timelines are driving the adoption of AI-driven platforms, improving efficiency and reducing failure rates. For instance, in February 2026, Takeda announced a multi-year collaboration with Iambic Therapeutics valued at over USD 1.7 billion to advance AI-based small-molecule drug discovery for oncology and gastrointestinal diseases. The partnership leverages de novo drug design, target identification, and protein structure prediction to enhance pipeline productivity and clinical trial failure reduction risks during the forecast period.

Artificial Intelligence in Drug Discovery Market Segmentation

Market Breakup by Process

• Target Identification and Selection
• Target Validation
• Hit Identification and Prioritization
• Hit-To-Lead Identification/Lead Generation
• Lead Optimization
• Candidate Selection and Validation

Market Breakup by Technology

• Machine Learning
• Natural Language Processing
• Context-Aware Processing and Computing
• Computer Vision
• Image Analysis

Market Breakup by Deployment

• On Premise Deployment
• Cloud Based Deployment
• SAAS Based Deployment

Market Breakup by Application

• Oncology
• Infectious Disease
• Neurology
• Metabolic Diseases
• Cardiovascular Diseases
• Immunology
• Mental Health Disorders
• Others

Market Breakup by End User

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Artificial Intelligence in Drug Discovery Market Share

Oncology Expected to Dominate the Market Segment by Application

The market is divided into oncology, infectious disease, neurology, metabolic diseases, cardiovascular diseases, immunology, mental health disorders, and others, based on the application. Among these, the oncology segment emerged as the major application, accounting for nearly 24% of the revenue share during the historical period. This growth is largely supported by the increasing prevalence of cancer and the expanding use of AI in identifying drug targets, discovering biomarkers, and streamlining clinical trials. Furthermore, sustained investments by pharmaceutical companies in oncological research continue to reinforce the segment’s dominant position in the market.

Global Artificial Intelligence in Drug Discovery Market Analysis by Region

The regions included in the market are North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America held a significantposition in the market, contributing approximately 52% of the total revenue share during the historical period. This prominence is driven by the strong presence of major technology and pharmaceutical players, well-established healthcare infrastructure, and significant R&D spending. In addition, favorable regulatory support and rapid adoption of advanced AI technologies further strengthen the region’s market position.

Leading Players in Artificial Intelligence in Drug Discovery Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

IBM Corporation

IBM Corporation is a US-based multinational technology company headquartered in Armonk, New York, founded in 1911. IBM leverages its Watson platform to accelerate data-driven research, enabling target identification, clinical trial optimization, and molecular discovery. The company collaborates with pharmaceutical firms and research institutions to enhance drug development efficiency through advanced analytics and machine learning capabilities.

Deep Genomics

Deep Genomics is a Canada-based biotechnology company headquartered in Toronto, established in 2015. The company specializes in AI-driven RNA biology to identify novel drug targets and genetic therapies. Its proprietary platform uses machine learning to predict the effects of genetic mutations, supporting precision medicine and accelerating therapeutic development, particularly for rare diseases and genetic disorders.

Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals, Inc. is a US-based biotechnology company headquartered in North Carolina, founded in 2013. It focuses on AI-powered drug design using its Quantum Molecular Design platform, which integrates physics-based modeling and machine learning. The company develops novel therapeutics across oncology and other disease areas, enabling faster identification of drug candidates with improved efficacy and reduced development timelines.

Microsoft Corporation

Microsoft Corporation is a US-based multinational technology company headquartered in Redmond, Washington, established in 1975. In the AI-driven drug discovery space, Microsoft provides cloud-based AI tools through Azure, supporting data integration, predictive modeling, and collaboration. The company partners with pharmaceutical and biotech firms to accelerate drug development processes using scalable computing, advanced analytics, and artificial intelligence technologies.

Other key players in the market are Exscientia, NVIDIA Corporation, Insilico Medicine, Atomwise, Inc., Biosymetrics, and Euretos.

Key Questions Answered in the Artificial Intelligence in Drug Discovery Market

• What was the artificial intelligence in drug discovery market value in 2025?
• What is the artificial intelligence in drug discovery market forecast outlook for 2026-2035?
• What major factors aid the demand for artificial intelligence in drug discovery market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major artificial intelligence in drug discovery market trends?
• Which process is expected to dominate the market segment?
• Which technology is projected to lead the market segment?
• Which deployment is projected to lead the market segment?
• Which application is projected to lead the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players in the artificial intelligence in drug discovery market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?